Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

NCT07030569 is registered in ClinicalTrials.gov with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor.

NCT NCT07030569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07030569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Observational
Overall status
Recruiting
Start date
February 1, 2024
Completion date
January 1, 2027
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer metastatic, breast cancer stage iv, breast cancer with bone metastasis, breast cancer with metastatic bone disease, breast carcinoma, breast neoplasms, her2, her2 + breast cancer, her2 positive breast carcinoma, her2-positive breast cancer, her2/neu positive advanced solid tumors, her2/neu-positive breast cancer, radiomic, radiomics, trastuzumab